Pharma Mirror

MARCH 29, 2022

NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.

Manufacturing 130

Manufacturing Production Development RNA 130

Pharmaceutical Technology

DECEMBER 19, 2023

BioNTech has inaugurated a new messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda, which will have BioNTainers.

Manufacturing 130

Manufacturing Vaccine Vaccination RNA 130

Pharmaceutical Technology

AUGUST 17, 2022

Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. By self-circularisation, Orna’s oRNA technology makes circular ribonucleic acids (oRNAs) from linear RNAs.

RNA 147

RNA Vaccine Vaccination In-Vivo 147

Pharma Times

OCTOBER 7, 2021

Leading RNA intereference (RNAi) therapeutics company, Alnylam, has been welcomed as the latest partner in the Medicines Manufacturing Innovation Centre, to transform the manufacturing process of oligonucleotide therapies.

Manufacturing 120

Manufacturing Medicine RNA 120

Bio Pharma Dive

OCTOBER 6, 2022

A new agreement with the Australian government will bring messenger RNA research and manufacturing capabilities to the country, adding to the COVID-19 vaccine developer’s global expansion efforts.

RNA 200

RNA Manufacturing Vaccine Vaccination 200

BioPharma Reporter

NOVEMBER 25, 2021

GreenLight Biosciences and CDMO Samsung Biologics have announced a partnership agreement, with Samsung Biologics to manufacture GreenLightâs messenger RNA COVID-19 vaccine candidate at commercial scale.

Manufacturing 105

Manufacturing Vaccine Vaccination RNA 105

pharmaphorum

AUGUST 16, 2022

Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 Now, Merck has made its own play, partnering with Orna on its proprietary ‘oRNA’ technology, which stands for circular RNA. billion, including $150 million upfront.

RNA 98

RNA Vaccination Vaccine Clinical Trials 98

BioPharma Reporter

SEPTEMBER 18, 2024

The new company focuses on producing components needed to manufacture RNA-based therapies for which there is increasing demand.

RNA 59

RNA Manufacturing Contract Manufacturing 59

Pharmaceutical Technology

NOVEMBER 22, 2022

Messenger RNA vaccines contain nucleic acids that code for a specific protein, or target antigen, related to a virus or disease. This approach to vaccination offers many advantages to developers, including quick development, high potency, a favorable safety profile, and the potential for cost-effective manufacturing.

Manufacturing 130

Manufacturing Vaccination Vaccine RNA 130

pharmaphorum

MAY 10, 2021

BioNTech has said it plans to set up a regional base and new manufacturing site in Singapore so that the biotech can keep pace with demand for its mRNA-based coronavirus vaccine and pipeline products in other disease areas. The post BioNTech to set up mRNA manufacturing site in Singapore appeared first on.

Manufacturing 129

Manufacturing Vaccination Vaccine Protein 129

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. The technology is designed to replace antibodies, which have become standard therapy in many diseases but are complicated and expensive to manufacture.

RNA 98

RNA Drugs Protein Immune Response 98

Pharmaceutical Technology

AUGUST 1, 2022

In March, the company entered a licensing agreement with Serum Institute of India (SII) to expedite access to messenger RNA products in emerging markets worldwide. In November last year, GreenLight and Samsung Biologics entered a collaboration agreement to manufacture mRNA Covid-19 vaccines.

Vaccine 245

Vaccine Vaccination Development RNA 245

Pharmaceutical Technology

AUGUST 2, 2022

Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Last year, the companies entered a strategic collaboration. This will enable GreenLight to commercially deliver the mRNA vaccine.

Engineer 262

Engineer Vaccine Vaccination Clinical Trials 262

Pharmaceutical Technology

AUGUST 6, 2024

SK pharmteco has entered an MoU with South Korea-based Rznomics for the development and manufacture of RNA-based gene therapies.

Gene Therapy 130

Gene Therapy Gene Development RNA 130

BioPharma Reporter

JULY 12, 2024

RNA therapeutics have emerged as a transformative approach to treating many conditions, but the industry still typically relies on inefficient batch manufacturing methods.

RNA 52

RNA Manufacturing Contract Manufacturing 52

BioSpace

JULY 30, 2024

The advantages of using circular RNAs—including increased durability, enhanced protein expression, and substantially lower manufacturing costs compared to linear mRNAs—have driven a spate of investment in this technology.

RNA 100

RNA Protein Manufacturing 100

Pharmaceutical Technology

JUNE 8, 2023

DTx-1252 is a fatty acid ligand conjugated oligonucleotides (FALCON) small interfering RNA (siRNA) therapeutic which represses the PMP22 gene in Schwann cells. FALCON siRNAs can be manufactured at low cost and delivered intrathecally [via the spine], intravenously and subcutaneously.

Drugs 246

Drugs Gene Therapy Gene RNA 246

XTalks

JANUARY 21, 2025

TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.

Bioassay 130

Bioassay RNA Development Drugs 130

Pharma Mirror

FEBRUARY 2, 2022

Global contract development and manufacturing organisation (CDMO), Recipharm, has today announced the acquisition of GenIbet, a Portuguese CDMO, specialising in the manufacture of biological clinical trial material and novel modalities such as viral vectors, RNA and microbiome.

RNA 130

RNA Manufacturing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MAY 25, 2023

The technology platforms include the Life Edit gene editing platform, an RNA, cell, protein, vector engineering and induced pluripotent stem cells (iPSCs) platform. ElevateBio intends to use the funds to advance its genetic medicine current good manufacturing practice (cGMP) and process development business, BaseCamp.

Gene Therapy 243

Gene Therapy Gene Gene Editing Development 243

BioPharma Reporter

JANUARY 23, 2023

Charles River Laboratories International, Inc and Rznomics Inc, a South Korea-based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, have established a viral vector contract development and manufacturing organization (CDMO) partnership.

Gene 110

Gene Gene Therapy Development RNA 110

XTalks

FEBRUARY 24, 2025

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59

Trials RNA Allergies Drugs 59

World of DTC Marketing

DECEMBER 29, 2020

Both the Pfizer and Moderna vaccines copied RNA sequence from the virus genome and found a way to manufacture it at scale with high-level processes and quality control. First, a novel approach was used that didn’t require traditional vaccine production in cell cultures or eggs. 1455NO-HEALTH-CORONAVIRUS_VACCINES_PFIZER_O_.

Vaccine 307

Vaccine Vaccination Development Clinical Trials 307

Pharmaceutical Technology

MAY 8, 2023

Innovation S-curve for the pharmaceutical industry ssRNA virus peptides is a key innovation area in pharmaceutical Single-stranded RNA (ssRNA) viruses establish a platform for viral replication in the cytoplasm during the early stages of infection and efficiently generate mature virus.

RNA 240

RNA Genetics Vaccination Vaccine 240

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccine 52

BioPharma Reporter

MARCH 17, 2022

Nutcracker Therapeutics, a biotech developing RNA therapeutics using its proprietary biochip-based manufacturing platform, has raised $167m in Series C financing: allowing it to expand and advance its pipeline of mRNA medicines for cancer and further refine its RNA manufacturing platform.

Manufacturing 52

Manufacturing RNA Medicine Development 52

BioPharma Reporter

MARCH 29, 2022

eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the eTheRNA group, has introduced a new lipid nanoparticle (LNP) formulation, development and production service.

Manufacturing 52

Manufacturing RNA Production Development 52

BioPharma Reporter

SEPTEMBER 16, 2021

AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.

RNA 88

RNA DNA Manufacturing 88

Pharmaceutical Technology

APRIL 3, 2023

The company has been recently focusing on plasmid design and manufacturing through acquisitions of Xpress Biologics this year and e-Zyvec in 2022. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies. The Sartorius-Polyplus deal is expected to close in Q3 2023.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

pharmaphorum

AUGUST 31, 2021

Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. The post ‘Endless RNA’ startup Laronde raises $440m to fuel pipeline appeared first on.

RNA 52

RNA Protein Immune Response Medicine 52

Scienmag

MARCH 4, 2021

Findings explain how plants use RNA to defend against fungal invaders Credit: Nicole Ward Gauthier/University of Kentucky New research reveals an essential step in scientists’ quest to create targeted, more eco-friendly fungicides that protect food crops.

Protein 95

Protein RNA Scientist Manufacturing 95

Roots Analysis

AUGUST 16, 2023

However, synthesis and manufacturing of mRNA is fraught with several challenges as the production of such biomolecules is complex, cost intensive, requires specialized expertise and dedicated equipment. Safety, efficacy and rapid production of mRNA drives the interest in this domain.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Marketing RNA 52

Pharmaceutical Technology

JANUARY 12, 2023

The collaboration will use the vector biology, manufacturing capabilities and the drug development experience of Solid Biosciences and Phlox Therapeutics’ knowledge in genetic cardiomyopathies and RNA therapies. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

RNA 130

RNA Gene Therapy Genetics Genetic Disease 130

XTalks

DECEMBER 22, 2021

The RNA Revolution: From mRNA Vaccines to RNA Editing. The age of RNA is officially here, and it’s here to stay as more than a passing life science trend. Formulas can be generated in days and clinical-grade manufacturing can be accomplished in weeks. RNA technology is not new nor has its potential been surprising.

Life Science 98

Life Science RNA Vaccination Vaccine 98

XTalks

FEBRUARY 3, 2022

billion into building new manufacturing plants in the US and Ireland to help boost production capacities. The company is investing $1 billion of the budget into a brand-new manufacturing facility in Concord, North Carolina in the US. million towards a new manufacturing site. Eli Lilly is sinking almost $1.5

Manufacturing 52

Manufacturing RNA Life Science Antibody 52

Roots Analysis

OCTOBER 22, 2023

RNA therapeutics are a novel class of biopharmaceuticals that harness the power of RNA molecules for the treatment and prevention of a wide range of disorders, including oncological, and genetic disorders as well as infectious diseases. Non-coding RNAs include antisense oligonucleotides (ASOs) and RNA aptamers.

RNA 40

RNA Protein Genetics Gene Expression 40